Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer

Hui Ju Ch'ang, Chin Lun Huang, Hsiu Po Wang, Her Shyong Shiah, Ming Chu Chang, Chang Ming Jan, Jen Shi Chen, Yu Wen Tien, Tsann Long Hwang, Jaw Town Lin, Ann Lii Cheng, Jacqueline Whang-Peng, Li Tzong Chen

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy and safety profile of a triplet regimen consisting of gemcitabine, oxaliplatin, and infusional fluorouracil and leucovorin (LV) in advanced pancreatic carcinoma (APC). Patients and methods: Chemotherapy-naïve patients with histo-/cytologically proven unresectable APC, and bi-dimensionally measurable diseases were eligible. Treatment consisted of fixed-dose rate (10 mg/m2/min) infusion of 800 mg/m2 gemcitabine followed by 2-h infusion of 85 mg/m2 oxaliplatin and then 48-h infusion of fluorouracil and LV (3,000 and 300 mg/m2, respectively) every 2 weeks (the GOFL regimen). The primary end-point was objective response rate. Results: Forty-five patients were enrolled and received a median of seven [95% confidence interval (CI) 6.4-8.8] cycles of treatment. On intent-to-treat analysis, the overall response and disease-control rates were 33.3% (95% CI 21.4-48.0%) and 68.9% (95% CI 54.8-83.0%), respectively. Clinical benefit response was observed in 46.2% of initially symptomatic patients. The median time-to-tumor progression and overall survival were 5.1 (95% CI 4.0-6.3) months and 8.7 (95% CI, 6.1-11.3) months, respectively. Major grade 3-4 toxicities were neutropenia (28.9%, with 4.4% complicated with fever), peripheral sensory neuropathy (15.6%), nausea/vomiting (13.3%), and diarrhea (6.7%). Conclusions: The triplet regimen is feasible and exhibits promising activity against APC, deserving further exploration.

Original languageEnglish
Pages (from-to)1173-1179
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume64
Issue number6
DOIs
Publication statusPublished - Nov 2009
Externally publishedYes

Keywords

  • Fluorouracil
  • Gemcitabine
  • Oxaliplatin
  • Pancreatic cancer
  • Phase II

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Fingerprint Dive into the research topics of 'Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer'. Together they form a unique fingerprint.

Cite this